HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,598 | +5.9% | 68 | 0.0% | 0.00% | – |
| Q2 2023 | $2,453 | -15.5% | 68 | -10.5% | 0.00% | -100.0% |
| Q1 2023 | $2,902 | -32.9% | 76 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $4,324 | +44.1% | 76 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $3,000 | 0.0% | 76 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $3,000 | 0.0% | 76 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $3,000 | 0.0% | 76 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $3,000 | +200.0% | 76 | +192.3% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 26 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 26 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | -50.0% | 26 | -43.5% | 0.00% | – |
| Q4 2020 | $2,000 | +100.0% | 46 | +100.0% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 23 | 0.0% | 0.00% | – |
| Q2 2020 | $1,000 | – | 23 | +27.8% | 0.00% | – |
| Q1 2020 | $0 | – | 18 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 18 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |